MAPK14 and kidney cancer: This led us to question whether a non‐invasive method to differentiate benign renal tumors and kidney cancer could be performed by analyzing patients’ urine for both miRs, namely miR‐498 and miR‐15a, in addition to the much cheaper and faster ELISA analysis of the target proteins (Vim3 and Mxi‐2).